Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Chanan-Khan

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
Clinical Case Reports|December 22, 2021
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literatureMizba Baksh, Liuyan Jiang, Unnati Bhatia, et al.
Cancer|November 14, 2015
Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysisSikander Ailawadhi, Pooja Advani, Dongyun Yang, et al.
Leukemia & Lymphoma|November 17, 2006
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolismKena C Miller, Swaminathan Padmanabhan, Laurie Dimicelli, et al.
Chemical Biology & Drug Design|April 10, 2015
Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15Xin Wang, Pádraig D'Arcy, Thomas R Caulfield, et al.
Leukemia & Lymphoma|December 29, 2004
Arterial thrombosis in four patients treated with thalidomideSarah L Scarpace, Theresa Hahn, Hilary Roy, et al.
HIV Clinical Trials|May 29, 2002
Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDSZale P Bernstein, Stephen P Brooks, Asher Chanan-Khan, et al.
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Clinical Case Reports|February 10, 2022
Myelomatous ascites and pleural effusion in relapsed multiple myelomaMizba Baksh, Ke Li, Liuyan Jiang, et al.
Leukemia & Lymphoma|September 17, 2004
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphomaAsher Chanan-Khan, Tariq Islam, Arif Alam, et al.
Molecular Cancer Research : MCR|May 3, 2012
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiationJennifer Blickwedehl, Scott Olejniczak, Ryan Cummings, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
Clinical Case Reports|December 22, 2021
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literatureMizba Baksh, Liuyan Jiang, Unnati Bhatia, et al.
Cancer|November 14, 2015
Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysisSikander Ailawadhi, Pooja Advani, Dongyun Yang, et al.
Leukemia & Lymphoma|November 17, 2006
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolismKena C Miller, Swaminathan Padmanabhan, Laurie Dimicelli, et al.
Chemical Biology & Drug Design|April 10, 2015
Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15Xin Wang, Pádraig D'Arcy, Thomas R Caulfield, et al.
Leukemia & Lymphoma|December 29, 2004
Arterial thrombosis in four patients treated with thalidomideSarah L Scarpace, Theresa Hahn, Hilary Roy, et al.
HIV Clinical Trials|May 29, 2002
Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDSZale P Bernstein, Stephen P Brooks, Asher Chanan-Khan, et al.
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Clinical Case Reports|February 10, 2022
Myelomatous ascites and pleural effusion in relapsed multiple myelomaMizba Baksh, Ke Li, Liuyan Jiang, et al.
Leukemia & Lymphoma|September 17, 2004
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphomaAsher Chanan-Khan, Tariq Islam, Arif Alam, et al.
Molecular Cancer Research : MCR|May 3, 2012
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiationJennifer Blickwedehl, Scott Olejniczak, Ryan Cummings, et al.
Pageof 11